Tracers / [177Lu]Lu-DOTA-KiSS-34

[177Lu]Lu-DOTA-KiSS-34

Also written as [Lu-177]Lu-DOTA-KiSS-34
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
—
Stage
preclinical study
Syntheses indexed
1
Breast cancerPreclinical only, no clinical indication yet

What it is

Compound class
DOTA-conjugated KISS1R-targeting peptide (hybrid kisspeptin analogue)
Target / mechanism
KISS1R (kisspeptin receptor) PMID 41774810
Clinical application
—
Theranostic pair
<a href="/tracers/ga68-dotakiss34/">ga68-dotakiss34</a>

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesis—none99.7——41774810
2026 Mol Pharm
1.5\u20136.0 \u03bcL of 177LuCl3 (3.0\u201310.0 MBq/81.1\u2013270.3 \u03bcCi) was transferred into a 1.5 mL Eppendorf tube (Protein LoBind), and 50 \u03bcL of NaOAc buffer (0.4 M, pH 5.0, Merck, Darmstadt, Germany) was added. — [177Lu]Lu-DOTA-KiSS-3499.7 (n = 10)

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-KiSS-34, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41774810. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41774810: 'the hybrid peptide KiSS-34 (AMBA-2-Nal-Gly-Leu-Arg-Trp-NH2)'. Stage set/updated at stage 23 from PMID 41774810: 'In this study, N-terminally functionalized conjugates of KP-10, KP-54, and the hybrid peptide KiSS-34 (AMBA-2-Nal-Gly-Leu-Arg-Trp-NH2), including scrambled controls, were synthesized in high purity (≥95%) for comparative studies.'.